289 related articles for article (PubMed ID: 2566377)
1. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J
Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377
[TBL] [Abstract][Full Text] [Related]
2. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene.
Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174
[TBL] [Abstract][Full Text] [Related]
5. Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma.
Kitagawa Y; Ueda M; Ando N; Shinozawa Y; Shimizu N; Abe O
Cancer Res; 1991 Mar; 51(5):1504-8. PubMed ID: 1997190
[TBL] [Abstract][Full Text] [Related]
6. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas.
Meyers SL; O'Brien MT; Smith T; Dudley JP
Cancer Res; 1990 Sep; 50(18):5911-8. PubMed ID: 1975511
[TBL] [Abstract][Full Text] [Related]
8. Proto-oncogene amplification and human breast tumor phenotype.
Adnane J; Gaudray P; Simon MP; Simony-Lafontaine J; Jeanteur P; Theillet C
Oncogene; 1989 Nov; 4(11):1389-95. PubMed ID: 2554239
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
10. [New prognostic factors in patients with esophageal squamous carcinoma].
Ueda M
Gan To Kagaku Ryoho; 1992 Jan; 19(1):20-5. PubMed ID: 1530906
[TBL] [Abstract][Full Text] [Related]
11. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
[TBL] [Abstract][Full Text] [Related]
12. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
13. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?
Tang RP; Kacinski B; Validire P; Beuvon F; Sastre X; Benoit P; dela Rochefordière A; Mosseri V; Pouillart P; Scholl S
J Cell Biochem; 1990 Nov; 44(3):189-98. PubMed ID: 1980125
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.
Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM
J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
16. c-erbB-2 amplification in node-negative human breast cancer.
Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424
[TBL] [Abstract][Full Text] [Related]
17. [Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erbB-2) and correlation with prognosis in 143 cases of resected lung cancer].
Chiba W; Sawai S; Hanawa T; Ishida H; Matsui T; Kosaba S; Watanabe S; Hatakenaka R; Matsubara Y; Funatsu T
Gan To Kagaku Ryoho; 1993 Apr; 20(6):824-7. PubMed ID: 8098200
[TBL] [Abstract][Full Text] [Related]
18. BCL-1 participates in the 11q13 amplification found in breast cancer.
Theillet C; Adnane J; Szepetowski P; Simon MP; Jeanteur P; Birnbaum D; Gaudray P
Oncogene; 1990 Jan; 5(1):147-9. PubMed ID: 2181375
[TBL] [Abstract][Full Text] [Related]
19. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA
Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785
[TBL] [Abstract][Full Text] [Related]
20. Quantitative detection of amplification of proto-oncogenes in breast cancer.
Chen Y; Dong J; Lu Y; McGee JO
Chin Med J (Engl); 1995 Nov; 108(11):849-54. PubMed ID: 8585979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
